<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940114-2-00076</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=56 g=1 f=1 -->  <DOCTITLE>Prospective Grant of Exclusive License: Cell Stress Transcriptional Factors</DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> National Institutes of Health, Public Health Service, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Notice. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the invention embodied in U.S. Patent Application SN 07/617,910, entitled ``Cell Stress Transcriptional Factors'' to StressTech Biomedical, Inc. of San Francisco, CA. The patent rights in this invention have been assigned to the United States of America. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. It is anticipated that this license will be limited to the fields of commercial screening assay services and kits provided to third parties. This prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> The patent application is based upon the observation that activation of heat shock proteins in an organism indicates elevated or environmental temperatures or a variety of other environmental stresses. Activation involves binding of a heat shock factor (HSF) to heat shock elements (HSE) and consequent transcription of heat shock genes. This method for detecting the accumulation of HSF in the nucleus of stressed cells involves novel activators for  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Drosophilia <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  and human HSF, polynucleotides encoding those activators, and antibodies to natural and recombinant DNA. The method may also be used to monitor and diagnose the effects of abnormal stresses, including disease, on cells. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </SUMMARY> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Requests for a copy of this patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Mr. Steven M. Ferguson, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, Box OTT, Bethesda, MD 20892. Telephone: (301) 496&hyph;7735; Facsimile: (301) 402&hyph;0220. A signed Confidentiality Agreement will be required to receive a copy of the patent application. Applications for a license in the indicated exclusive fields filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by NIH within sixty (60) days of this notice will be considered. <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: January 3, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ADDRESS> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Donald P. Christoferson, <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Acting Director, Office of Technology Transfer. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;908 Filed 1&hyph;13&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4140&hyph;01&hyph;M <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            